Golden Throat (06896) disclosed the 2023 annual results announcement. The group achieved revenue of 961 million yuan during the reporting period (...
According to the Zhitong Finance App, Golden Throat (06896) disclosed the 2023 annual results announcement. The group achieved revenue of 961 million yuan (RMB, same below) during the reporting period, a year-on-year decrease of 3.09%. Gross profit was $698 million, down 3.22% year over year. Profit attributable to the company's equity holders was 250 million yuan, a year-on-year decrease of 11.04%. Earnings per share were 33.84 points. A proposed final dividend of HK$0.6 per share.
Sales of Golden Throat Throat Tablets (OTC) remained stable in 2023. For the year ended December 31, 2023, the group's revenue from sales of Golden Throat Throat Tablets (OTC) was approximately 865 million yuan, a year-on-year decrease of 4.4%. There was no significant change in the amount compared to the same period last year.